Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2011. The report details a specific share repurchase transaction executed on April 12, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to a share buyback.
- Shares Purchased: 650,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,236.5 pence per share; lowest price paid was 1,221 pence per share.
- Treasury Shares Held: 493,224,284 shares (representing 8.71% of total issued share capital and 9.54% of total voting rights).
- Shares in Issue: 5,167,038,881 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding share capital through the cancellation of 650,000 repurchased shares. This action increased the proportion of Treasury shares held by the Company relative to the total issued share capital.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,167,038,881) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (493,224,284) and its impact on voting rights (9.54%).
- Note that the repurchased shares were cancelled, permanently reducing the company's share count.